Thursday, June 13, 2013
Although GlaxoSmithKline plc has quietly shuttered its Center of Excellence for
External Drug Discovery (CEEDD), the pharma maintains it is not deprioritizing
early program partnerships. Instead, GSK thinks its R&D scientists have
adopted the strategies brought in by CEEDD, and that there is no longer a need
for a group dedicated to creating external alliances.
C.S. SciBX 6(23);
Published online June 13, 2013
1. Fulmer, T. BioCentury
21(22), A1-A6; June 3, 2013
2. Osherovich, L. SciBX
AND INSTITUTIONS MENTIONED
ChemoCentryx Inc., Mountain View, Calif.
GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London, U.K.
Prosensa B.V., Leiden, the Netherlands